AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6734925
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin (acetyl salicylic acid)
Trial: 30953536
Drug: Short-term mentalization-based
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term mentalization-based therapy (20 weeks)
Trial: 30953536
Drug: Long-term mentalization-based
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term mentalization-based therapy (14 months)
Trial: 26461858
Drug: Intervention (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (10 weekly educational sessions led by promotoras)
Trial: 23788755
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival (OS) from start of induction chemotherapy
Trial: 11815493
Drug: Culturally competent
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally competent diabetes self-management education intervention over 12 months, consisting of 52 contact hours, including 3 months of weekly sessions and 6 months of biweekly support group sessions.
Trial: 10414041
Drug: Quinine (750-850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (750-850 mg for 24 hours over 4.1 +/- 1.7 days)
Trial: 2027071
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg to start and 100 mg per day for 3 weeks)
Trial: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 30 mg
Trial: 7250175
Drug: Sustained released
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained released ISDN 20 mg
Trial: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 20-30 mg
Trial: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 5 mg
Trial: 7250175
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 10 to 50 mg
Trial: 29053202
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 (20 μg/day)
Trial: 29053202
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 (40 μg/day)
Trial: 29053202
Drug: Ex-BID (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex-BID (10 μg BID)
Trial: 29053202
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 (after 3-fold dose escalation)
Trial: 27956826
Drug: Trimebutine 200
RxNorm normalized name: trimebutine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine 200 mg three times daily half an hour before meals
Trial: 27956826
Drug: Probiotics (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (60 mg per-tablet of Lactobacillus acidophilus and Bifidobacterium infantis), 2×/d, 1 hour after meals
Trial: 23602614
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (500 mL daily)
Trial: 23602614
Drug: Hesperidin (292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hesperidin (292 mg in a capsule with isocaloric control beverage)
Trial: 22076245
Drug: Ecstasy (MDMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecstasy (MDMA 100 mg) and Alcohol (BAC 0.5‰)
Trial: 1873888
Drug: Albendazole 8-10
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 8-10 mg/kg.d, 2-3 times a day for 30 days, followed by a 10-day break, continued for 3-12 months (Group I, 72 cases)
Trial: 1873888
Drug: Albendazole 15.6-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 15.6-20 mg/kg.d for 14 days, every two weeks with a 10-day interval for 3-6 months (Group II, 8 cases)
Trial: 6224046
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg MPA p.o. daily
Trial: 6224046
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg MPA i.m. on 5 days per week
Trial: 6224046
Drug: Hormone profile
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone profile monitoring (cortisol and prolactin)
Trial: 26942907
Drug: Deprescribing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deprescribing intervention (n = 47) - planned cessation of non-beneficial medicines
Trial: 20635179
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alcohol (0.8 g/kg)
Trial: 20635179
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of alcohol (0.4 g/kg)
Trial: 12195763
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg for 3 days, then 50 mg for 4 days (15 mg and 30 mg for patients over 65 years)
Trial: 7986242
Drug: Commercial tablet
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial tablet
Trial: 3141891
Drug: GHRH administered
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administered subcutaneously every 3 hours (n = 10)
Trial: 3141891
Drug: GHRH administered
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administered subcutaneously every 3 hours overnight only (n = 10)
Trial: 3141891
Drug: GHRH administered
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH administered by twice daily injections (n = 4)
Trial: 3141891
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment with GHRH (n = 16)
Trial: 3141891
Drug: GHRH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH therapy (n = 11 with circulating antibodies)
Trial: 5018311
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose as diluent for heparin
Trial: 5018311
Drug: 5% sorbitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sorbitol as diluent for heparin
Trial: 27720838
Drug: Elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) for 12 weeks
Trial: 27720838
Drug: Elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 12 weeks
Trial: 27720838
Drug: Elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) for 16 weeks
Trial: 27720838
Drug: Elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 16 weeks
Trial: 14990402
Drug: 52.5 mg
RxNorm normalized name: carbidopa 52.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52.5 mg gel
Trial: 14990402
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg gel
Trial: 14990402
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg gel
Trial: 14990402
Drug: Film (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film (100 mg)
Trial: 14990402
Drug: Suppository (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository (100 mg)
Trial: 11720694
Drug: Ipsapirone (IPS)
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone (IPS) 0.5 mg/kg, p.o.
Trial: 9257201
Drug: Dolasetron mesilate
RxNorm normalized name: Dolasetron mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesilate 12.5 mg
Trial: 3526900
Drug: Motrin (ibuprofen)
RxNorm normalized name: ibuprofen Oral Tablet [Motrin]
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Motrin (ibuprofen)
Trial: 24225816
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g·kg‐1BM)
Trial: 24225816
Drug: Beta-alanine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (6.4 g·day‐1 for 4 weeks, 3.2 g·day‐1 for 1 week)
Trial: 22807611
Drug: sumatriptan 50
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan 50 mg
Trial: 17472478
Drug: Eclipta alba
RxNorm normalized name: Eclipta prostrata leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eclipta alba (3 g/day in encapsulated form)
Trial: 2563465
Drug: 3-monthly tympanometry
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-monthly tympanometry screening and subsequent treatment for OME
Trial: 28196255
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (daily tablets containing 15 µg of major allergen Phleum p 5)
Trial: 28196255
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched double-placebo injections)
Trial: 28196255
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (monthly injections containing 20 µg of Phleum p 5)
Trial: 16926775
Drug: saquinavir-SGC/ritonavir (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir-SGC/ritonavir (1600 mg/100 mg)
Trial: 15344394
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg once a day
Trial: 15344394
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice a day
Trial: 10937611
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for 14 weeks followed by placebo for 36 weeks
Trial: 10937611
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for 38 weeks followed by placebo for 12 weeks
Trial: 10937611
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for 50 weeks
Trial: 28639551
Drug: Facet joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facet joint injections (FJIs) with local anaesthetic and corticosteroids (at up to six injection sites) plus best usual care (BUC)
Trial: 24908148
Drug: Sublingual Diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Diazepam
Trial: 24908148
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment intervention)
Trial: 23731674
Drug: Antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiandrogen therapy combined with exercise (AE)
Trial: 23731674
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with exercise (CE)
Trial: 23731674
Drug: Antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiandrogen therapy without exercise (A)
Trial: 23731674
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without exercise (C)
Trial: 18258423
Drug: 20 microg
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg formoterol fumarate inhalation solution twice daily plus tiotropium (FFIS/TIO)
Trial: 18258423
Drug: Nebulized placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized placebo twice daily plus tiotropium (PLA/TIO)
Trial: 17069557
Drug: Suspension (hang-back)
RxNorm normalized name: Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension (hang-back) recession technique
Trial: 10866909
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 12 mL of 0.75% ropivacaine
Trial: 10866909
Drug: Multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injections of 4 mL of 0.75% ropivacaine at each muscular twitch
Trial: 9357393
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg every 24 hours (from day 11 to day 20) with losartan 100 mg every 24 hours
Trial: 9357393
Drug: Eprosartan 300
RxNorm normalized name: eprosartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 300 mg every 12 hours
Trial: 7950612
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (conventional treatment)
Trial: 2886560
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg captopril BID
Trial: 2886560
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg captopril BID
Trial: 2886560
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the dose of captopril (Phase 3)
Trial: 2886560
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus diuretic (Phase 4)
Trial: 2886560
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (beta blocker-diuretic treatment)
Trial: 23380881
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (ACE‐i)
Trial: 20826029
Drug: Actovegin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin (30 ml daily, 5 days/week) administered from day 1 of radiotherapy for Group 1 (prevention)
Trial: 20826029
Drug: Actovegin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin (30 ml daily, 5 days/week) administered from the onset of grade 2 mucositis for Group 2 (treatment)
Trial: 18097226
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruption (STI), cycles of 12 weeks on/off (408 participants)
Trial: 2859703
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg celiprolol once daily for 3 weeks
Trial: 2859703
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg celiprolol in combination with 12.5 mg chlorthalidone for 3 weeks
Trial: 2859703
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg celiprolol in combination with 25 mg chlorthalidone for 3 weeks
Trial: 2859703
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg celiprolol or in combination with 12.5 mg or 25 mg CT for up to 12 months
Trial: 2859703
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 25 mg CT
Trial: 29552766
Drug: Endostar combined
RxNorm normalized name: Menostar
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endostar combined with cisplatin/pemetrexed chemotherapy
Trial: 29552766
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (pemetrexed and cisplatin)
Trial: 27314599
Drug: Remifentanil TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil TCI (effect‐site concentration=1.5 ng.mL‐1)
Trial: 23121149
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg GEn
Trial: 23121149
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg GEn
Trial: 23121149
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg GEn
Trial: 18462268
Drug: Nonselective β‐blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective β‐blockers
Trial: 18462268
Drug: Nonselective β‐blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective β‐blockers (with isosorbide‐5‐mononitrate)
Trial: 18462268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nonselective β‐blockers and EBL
Trial: 2049361
Drug: Combination sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination sedation technique using nalbuphine and midazolam
Trial: 6755207
Drug: Regimens with
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimens with second-line drugs (cytosine arabinoside and asparaginase)
Trial: 31651842
Drug: Intravenous dexamethasone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexamethasone, administered twice daily for 48 hours
Trial: 31651842
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered twice daily for 48 hours
Trial: 27633946
Drug: Combined tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined tranexamic acid (IV and topical)
Trial: 27633946
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (IV)
Trial: 24607889
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive treatment (percutaneous plate via sinus tarsi approach)
Trial: 24607889
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (open reduction and internal fixation with conventional plate via L-shaped lateral approach)
Trial: 24607889
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive treatment
Trial: 14725849
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) with GABAergic mechanisms
Trial: 14725849
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) with glutamate reduction mechanisms
Trial: 14725849
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs with sustained effects on neuronal mechanisms
Trial: 14725849
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs with use-dependent impact on sodium or calcium channels
Trial: 14725849
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs with multiple mechanisms of action
Trial: 9799053
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg) pre-treatment for 4 days and co-administration with cerivastatin (0.3 mg)
Trial: 9799053
Drug: Cerivastatin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.3 mg) alone
Trial: 352184
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous injection
Trial: 25447301
Drug: 1M sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1M sucrose solution (SU)
Trial: 19555360
Drug: 3-month oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month oral function promotion programme including facial muscle and tongue exercises and salivary gland massages
Trial: 15692318
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement (400 IU vitamin E, 1 g vitamin C, 90 µg selenium per day)
Trial: 11928800
Drug: Systemic chemotherapy‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy‐based regimens
Trial: 7522487
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) as part of induction treatment for good-prognosis patients
Trial: 7522487
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with interferon (IFN)
Trial: 2572145
Drug: Alpidem (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpidem (150 mg/day, 50 mg t.i.d. for 3 weeks)
Trial: 4563483
Drug: Cyclobenzaprine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 60 mg/day
Trial: 4563483
Drug: Cyclobenzaprine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 150 mg/day